芦可替尼联合糖皮质激素对急性移植物抗宿主病中巨细胞病毒激活的影响
回顾性分析2018年8月至2020年9月解放军总医院第一医学中心195例异基因造血干细胞移植患者,按急性GVHD一线方案分为芦可替尼联合糖皮质激素组与单用糖皮质激素组。结果显示两组在移植后90天及180天CMV激活累积发生率、激活时长及转阴时长差异均无统计学意义(P值均>0.05),总生存率及无病生存率差异亦无统计学意义(P值均>0.05)。结论为芦可替尼联合糖皮质激素一线治疗急性GVHD不增加CMV激活风险。
要点
- 联合方案组与经典方案组Ⅰ~Ⅳ度急性GVHD患者移植后90天及180天CMV激活累积发生率差异无统计学意义(P值均>0.05)。
- Ⅱ~Ⅳ度及Ⅲ/Ⅳ度急性GVHD患者中,两方案CMV激活累积发生率、激活时长及转阴时长差异均无统计学意义(P值均>0.05)。
- 两组急性GVHD患者移植后2年总生存率及无病生存率差异均无统计学意义(P值均>0.05)。
核心结论
- 芦可替尼联合糖皮质激素一线治疗急性GVHD不增加CMV激活的风险。
研究设计与样本
- 回顾性分析2018年8月至2020年9月解放军总医院第一医学中心血液病科195例异基因造血干细胞移植患者的临床资料。
- 根据急性GVHD发生情况分为无、Ⅰ度、Ⅱ~Ⅳ度、Ⅲ/Ⅳ度急性GVHD组,根据一线治疗方案分为联合方案组(芦可替尼联合糖皮质激素)及经典方案组(单用糖皮质激素)。
主要发现
- 195例患者中无急性GVHD 64例(32.8%)、Ⅰ度急性GVHD 30例(15.4%)、Ⅱ~Ⅳ度急性GVHD 101例(51.8%)、Ⅲ/Ⅳ度急性GVHD 14例(7.2%)。
- 联合方案组与经典方案组Ⅰ~Ⅳ度急性GVHD患者在移植后90天及180天CMV激活累积发生率差异无统计学意义(P值均>0.05),CMV激活时长及转阴时长差异也无统计学意义(P值均>0.05)。
- 进一步对两种方案一线治疗Ⅱ~Ⅳ度及Ⅲ/Ⅳ度急性GVHD分析,移植后90天及180天CMV激活累积发生率、激活时长及转阴时长差异均无统计学意义(P值均>0.05)。
- 两组急性GVHD患者移植后2年总生存率及无病生存率差异均无统计学意义(P值均>0.05)。
关键数值与推荐
- 急性GVHD一线联合方案为芦可替尼联合糖皮质激素,经典方案为单用糖皮质激素。
- CMV激活评估时间点为移植后90天及180天,生存分析时间点为移植后2年。
临床怎么用
- 原文结论为芦可替尼联合糖皮质激素一线治疗急性GVHD不增加CMV激活的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the effect of ruxolitinib combined with glucocorticoid on cytomegalovirus (CMV) activation in patients with acute graft-versus-host disease (aGVHD) . Methods: The clinical data of 195 patients who underwent allogeneic hematopoietic stem cell transplantation in the Department of Hematology of the First Medical Center of the People's Liberation Army General Hospital from August 2018 to September 2020 were retrospectively analyzed. According to the severity of aGVHD, the patients were divided into the non-GVHD group, aGVHD grade Ⅰ group, aGVHD grade Ⅱ-Ⅳ group, and aGVHD grade Ⅲ/Ⅳ group. In addition, they were classified into two subgroups according to the first-line treatment regimen for aGVHD: combined regimen group (ruxolitinib combined with glucocorticoid) and classical regimen group (glucocorticoid alone) . The cumulative incidence of CMV activation, the duration of CMV activation, and the duration of CMV negativity in each subgroup at 90 and 180 days after transplantation were analyzed. The overall survival and disease-free survival rates of patients in both regimens were compared. Results: Sixty-four (32.8%) patients in the group did not develop aGVHD. The numbers of patients with grade Ⅰ, Ⅱ-Ⅳ, and Ⅲ/Ⅳ aGVHD were 30 (15.4%) , 101 (51.8%) , and 14 (7.2%) , respectively. Compared with patients in the classical regimen, no significant difference was observed in the cumulative incidence of CMV activation, duration of CMV activation, and duration of CMV negativity in patients with grade Ⅰ-Ⅳ aGVHD in the combined regimen at 90 and 180 days after transplantation (P>0.05) . Further analysis of patients with grade Ⅱ-Ⅳ and Ⅲ/Ⅳ aGVHD showed that the cumulative incidence of CMV activation, duration of CMV activation, and duration of CMV negativity did not show significant difference between the two treatment regimens (P>0.05) . In addition, there was no significant difference in the overall survival and disease-free survival rates of patients in both regimens (P>0.05) . Conclusion: Ruxolitinib combined with glucocorticoid as the first-line therapy for aGVHD did not increase the risk of CMV activation. 目的: 观察芦可替尼联合糖皮质激素一线治疗急性移植物抗宿主病(GVHD)对巨细胞病毒(CMV)激活的影响。 方法: 回顾性分析2018年8月至2020年9月期间195例在解放军总医院第一医学中心血液病科进行异基因造血干细胞移植患者的临床资料,根据急性GVHD发生情况分为无、Ⅰ度、Ⅱ~Ⅳ度、Ⅲ/Ⅳ度急性GVHD组,根据急性GVHD一线治疗方案分为联合方案组(芦可替尼联合糖皮质激素)及经典方案组(单用糖皮质激素)。分析移植后90 d及180 d各组CMV激活累积发生率、CMV激活时长及转阴时长,比较联合方案组及经典方案组总生存率及无病生存率。 结果: 195例患者中无急性GVHD 64例(32.8%)、Ⅰ度急性GVHD 30例(15.4%)、Ⅱ~Ⅳ度急性GVHD 101例(51.8%)、Ⅲ/Ⅳ度急性GVHD 14例(7.2%)。联合方案组、经典方案组Ⅰ~Ⅳ度急性GVHD患者在移植后90 d及180 d CMV激活累积发生率差异无统计学意义(P值均>0.05),且CMV激活时长及转阴时长差异也无统计学意义(P值均>0.05)。进一步对两种方案一线治疗Ⅱ~Ⅳ度及Ⅲ/Ⅳ度急性GVHD进行分析,发现在移植后90 d及180 d CMV激活累积发生率、激活时长及转阴时长差异均无统计学意义(P值均>0.05)。此外,两组急性GVHD患者移植后2年总生存率及无病生存率差异均无统计学意义(P值均>0.05)。 结论: 芦可替尼联合糖皮质激素一线治疗急性GVHD不增加CMV激活的风险。.
引用
- Xing SY, Qian K, Zhao YX, et al. [Effect of ruxolitinib combined with glucocorticoid on cytomegalovirus activation in acute graft-versus-host disease]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709166. doi:10.3760/cma.j.issn.0253-2727.2022.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。